Susceptibility to Type 1 Diabetes Is Associated With ApoCIII Gene Haplotypes
- John E. Hokanson1,
- Gregory L. Kinney1,
- Suzanne Cheng2,
- Henry A. Erlich2,
- Adam Kretowski34 and
- Marian Rewers13
- 1Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado
- 2Roche Molecular Systems, Alameda, California
- 3Barbara Davis Center for Childhood Diabetes, Aurora, Colorado
- 4Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
- Address correspondence and reprint requests to John E. Hokanson, PhD, Associate Professor, Department of Preventive Medicine and Biometrics, Box B119, University of Colorado Health Sciences Center, Denver, CO 80262. E-mail: john.hokanson{at}uchsc.edu
Abstract
Type 1 diabetes is a disease of β-cell destruction leading to insulin deficiency. Genes for type 1 diabetes have been identified; however, much of the genetic risk remains unexplained. Genetic variation within the apolipoprotein CIII (apoCIII) gene alters apoCIII levels, which are increased in type 1 diabetes and induce β-cell apoptosis. We therefore hypothesize haplotypes within the apoCIII gene are associated with type 1 diabetes. DNA from 584 type 1 diabetic patients and 591 control subjects were genotyped for six single nucleotide polymorphisms (SNPs) in the apoCIII gene (C-641A, C-482T, T-455C, C1100T, C3175G, and T3206G). Two alleles of a haplotype block (promoter SNPs + C3175G) were associated with type 1 diabetes. The A-T-C-C allele frequency was higher in type 1 diabetes (0.19 vs. 0.16, P = 0.05), and the C-C-T-C allele was reduced in type 1 diabetes (0.60 vs. 0.65, P = 0.04). The odds ratio (OR) for A-T-C-C allele increased with 0, 1, and 2 copies (OR of 1.00, 1.24, and 1.60, respectively; P = 0.05) and decreased for the C-C-T-C allele (1.00, 0.97, and 0.73, respectively; P = 0.03). This haplotype block contains an insulin response element. Screening for this haplotype may identify at-risk individuals, and this pathway may offer a target for prevention of type 1 diabetes.
Footnotes
-
- Accepted December 5, 2005.
- Received October 24, 2005.
- DIABETES














